Navamedic wins joint Nordic antibiotics tender

07 Oct 2024 13:57 CEST

Oslo, 07 October 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
reliable provider of high-quality products to hospitals and pharmacies, has
signed joint contracts with Amgros in Denmark, Landspitali Háskólasjúkrahús in
Iceland and Sykehusinnkjøp HF, divisjon legemidler in Norway to be the main
supplier of certain antibiotics to hospital across all three countries. The
contracts start in April 2025 and will run until 2027, with the opportunity for
an extension.

These are the latest of several tenders Navamedic has secured this year,
representing significant growth for the antibiotic's portfolio and predictable
income for the coming years. Together with the recently announced LIS tender,
these represent the largest antibiotics tenders in the Nordics.
"We consider securing this Nordic tender a testament to the quality of our
antibiotic portfolio and our position in the market. Our commitment to
responsible manufacturing of antibiotics has been a cornerstone of our strategy,
and we are proud to see it recognised with this significant tender win," says
Janne Folmoe, Tender Manager at Navamedic ASA.

With new global guidance aimed at reducing antibiotic pollution from
manufacturing, this Nordic tender emphasised the importance of the environment.
Pollution prevention and manufacturing control will play a significant role in
the fight against antimicrobial resistance, and manufacturers and suppliers will
be met with increasingly higher quality criteria. As a member of The AMR
Industry Alliance and with ISO certification, Navamedic has demonstrated that it
is a reliable and responsible supplier of antibiotics.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA).
For more information, please visit www.navamedic.com

More information:
Access the news on Oslo Bors NewsWeb site